| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A derivative of the insecticide dichlorodiphenyldichloroethane that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression. [PubChem] |
| Indication |
For treatment of inoperable adrenocortical tumours; Cushing's syndrome |
| Pharmacology |
Mitotane is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. The administration of Mitotane alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. The drug apparently causes increased formation of 6-B-hydroxyl cortisol. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic and renal |
| Absorption |
About 40% oral Lysodren is absorbed |
| Half Life |
18-159 days |
| Protein Binding |
6% |
| Elimination |
A variable amount of metabolite (1%-17%) is excreted in the bile and the balance is apparently stored in the tissues. |
| External Links |
|